Arkolith/Insider Trading/EBS/Form 4

Glessner Coleen

EVP, Quality & Ethics, and CPLEmergent BioSolutions Inc. (EBS) · full profile →Form 4 · filed Oct 16, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$306K
Net Open-Market Flow
-$306K
Transactions
1
1 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Oct 7, 2025Sell(S)31K$10.00$306K144K

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001919170-25-000004) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML